"Previous data from the trial reported that 107 participants received the mRNA vaccine and Keytruda treatment, while the remaining 50 only received Keytruda. At the two-year follow-up, 24 of the 107 (22 percent) who got the experimental vaccine and Keytruda had recurrence or death, while 20 of 50 (40 percent) treated with just Keytruda had recurrence or death, indicating a 44 percent risk reduction"Statistically, if those in the control group had gotten the treatment, then in expectation 9 of those people wouldn't have had their cancer return or died. It must be exciting to run these sorts of trials with super promising drugs, but also a little bittersweet/dark.
Hacker News